MiNK Therapeutics (INKT) reports Q2 2026 results; Phase 2 agenT-797 observations
MiNK Therapeutics (INKT) reports second-quarter 2026 financial results and observations from a randomized Phase 2 trial of agenT-797 in acute lung injury.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.